Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers

References

• Korthof ET, Bekassy AN, Hussein AA. Management of acquired aplastic anemia in children. Bone Marrow Transplant. 2013;48(2):191–195. doi:10.1038/bmt.2012.235
   PubMed Web of Science ®Google Scholar
• Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014;99(4):664–671.
   PubMed Web of Science ®Google Scholar
• Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119–2125. doi:10.3324/haematol.2010.026682
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436. doi:10.1182/blood-2016-08-693481
   PubMed Web of Science ®Google Scholar
• Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK paediatric BMT working party, paediatric diseases working party and severe aplastic anaemia working party of EBMT. Br J Haematol. 2015;171(4):585–594. doi:10.1111/bjh.13614
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Obara N, Kurita N, et al. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol. 2013;98(3):319–322. doi:10.1007/s12185-013-1418-5
   PubMed Web of Science ®Google Scholar
• Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. Blood. 2012;119(23):5391–5396. doi:10.1182/blood-2012-02-407684
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438. doi:10.1056/NEJMoa1103975
   PubMed Web of Science ®Google Scholar
• Atta EH, Dias DS, Marra VL, et al. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010;89(9):851–859. doi:10.1007/s00277-010-0944-y
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressivetreatment in the last decade: a report from the European Group for Blood and MarrowTransplantation (EBMT). Haematologica. 2007;92(1):11–18.
   PubMed Web of Science ®Google Scholar
• Chang MH, Kim KH, Kim HS, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84(2):154–159. doi:10.1111/j.1600-0609.2009.01378.x
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survivalin severe aplastic anaemia. Br J Haematol. 2009;144(2):206–216. doi:10.1111/j.1365-2141.2008.07450.x
   PubMed Web of Science ®Google Scholar
• Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: a single institution experience. Am J Hematol. 2017;92(12):1295–1302. doi:10.1002/ajh.24897
   PubMed Web of Science ®Google Scholar
• Peffault DLR, Tabrizi R, Marcais A, et al. Nationwide survey on the use of horse antithymocyte globulins(ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French reference centerfor aplastic anemia. Am J Hematol. 2018;93(5):635–642. doi:10.1002/ajh.25050
   PubMed Web of Science ®Google Scholar
• Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70. doi:10.1111/j.1365-2141.2009.07842.x
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016;104(2):168–174. doi:10.1007/s12185-016-2037-8
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie´ G, Hamladji RM, et al. Aplastic Anemia working party of the european group for blood marrow transplantation. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5):696–702. doi:10.3324/haematol.2014.115345
   PubMed Web of Science ®Google Scholar
• Marsh JC, Pearce RM, Koh MB, et al. British society for blood and marrow transplantation, clinical trials committee. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British society for blood and marrow transplantation. Bone Marrow Transplant. 2014;49(1):42–48. doi:10.1038/bmt.2013.115
   PubMed Web of Science ®Google Scholar
• Anderlini P, Wu J, Gersten I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a Phase 1–2 dose de-escalation study. Lancet Haematol. 2015;2(9):e367–e375. doi:10.1016/S2352-3026(15)00147-7
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol. 2016;172(2):187–207. doi:10.1111/bjh.13853
   PubMed Web of Science ®Google Scholar
• Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working party of the European group for blood and marrow transplantation. Blood. 2011;117(17):4434–4441.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784–1791. doi:10.3324/haematol.2014.109355
   PubMed Web of Science ®Google Scholar
• Nair V, Sondhi V, Sharma A, Das S, Sharma S. Survival after immunosuppressive therapy in children with aplastic anemia. Indian Pediatr. 2012;49(5):371–376. doi:10.1007/s13312-012-0086-5
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Aplastic anemia: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2007;2007(1):23–28. doi:10.1182/asheducation-2007.1.23
   Google Scholar
• Pediatric Hematology Study Group, Chinese Medical Association. Acquired Guidelines for the diagnosis and management of pediatric acquired aplastic anaemia. Zhonghua Er Ke Za Zh. 2014;52(2):103–106. in Chinese
   PubMedGoogle Scholar
• Xie X, Zhao H, Qin D, et al. Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia. Int J Clin Exp Med. 2015;8(3):4349–4355.
   PubMed Web of Science ®Google Scholar
• Feng X, Scheinberg P, Biancotto A, et al. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014;99(9):1433–1440. doi:10.3324/haematol.2014.106542
   PubMed Web of Science ®Google Scholar
• Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675–3683. doi:10.1182/blood-2008-01-130146
   PubMed Web of Science ®Google Scholar
• Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010;10(9):2132–2141. doi:10.1111/j.1600-6143.2010.03210.x
   PubMed Web of Science ®Google Scholar
• Bleyzac N, Philippe M, Bertrand A, et al. Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2015;100(5):e211–222. doi:10.3324/haematol.2014.122275
   PubMed Web of Science ®Google Scholar
• Brandt C, Pavlovic V, Radbruch A, et al. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009;64(11):1588–1596. doi:10.1111/j.1398-9995.2009.02054.x
   PubMed Web of Science ®Google Scholar
• Kawai M, Kitade H, Mathieu C, et al. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation. 2005;79(9):1073–1077. doi:10.1097/01.TP.0000153505.73700.32
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yang Y, Yang W, et al. Efficacy and safety of porcine ALG compared to rabbit ATG as first-line treatment for children with acquired aplastic anemia. Eur J Haematol. 2020;104(6):562–570. doi:10.1111/ejh.13398
   PubMed Web of Science ®Google Scholar
• Lin S, Hou L, Liu S, et al. Roles of regulatory T cells in the pathogenesis of pediatric aplastic anemia. Pediatr Hematol Oncol. 2019;36(4):1–13. doi:10.1080/08880018.2019.1621968
   PubMed Web of Science ®Google Scholar
• Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood. 2012;120(8):1624–1632. doi:10.1182/blood-2011-11-390708
   PubMed Web of Science ®Google Scholar
• Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016;128(9):1193–1205. doi:10.1182/blood-2016-03-703702
   PubMed Web of Science ®Google Scholar
• Lim SP, Costantini B, Mian SA, et al. Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction. Blood. 2020;136(7):885–897. doi:10.1182/blood.2019001347
   PubMed Web of Science ®Google Scholar
• Sasaki N, Shimura K, Yoshida M, et al. Kyoto Clinical Hematology Study Group (KOTOSG) investigators. Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients. Int J Hematol. 2019;109(3):278–285. doi:10.1007/s12185-018-02583-w
   PubMed Web of Science ®Google Scholar
• Lan Y, Chang L, Yi M, et al. Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine. Ann Hematol. 2021;100(1):53–61. doi:10.1007/s00277-020-04296-9
   PubMed Web of Science ®Google Scholar
• Li F, He W, Shi W, et al. Efficacy of rabbit antithymocyte globulin as a first-line therapy in children with aplastic anemia. J Pediatr Hematol Oncol. 2020;42(8):e702–e706. doi:10.1097/MPH.0000000000001885
   PubMed Web of Science ®Google Scholar
• Lin SF, Liu S, Xue HM, et al. Comparison of two dosages of rabbit antithymocyte globulin (r-ATG) in treating children with severe aplastic anemia. Pharmazie. 2018;73(5):264–268. doi:10.1691/ph.2018.7353
   PubMed Web of Science ®Google Scholar
• Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119–25. doi:10.1016/j.bbmt.2009.09.013
   PubMed Web of Science ®Google Scholar
• Gu C, Zhu X, Qiao X, et al. Multivariate logistic analysis of predictors of response to immunosuppressive therapy in children with aplastic anemia: a double-center study. Hematology. 2019;24(1):282–289.
   PubMed Web of Science ®Google Scholar